AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Subscribe To Our Newsletter & Stay Updated